Zonisamide for the treatment of Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 7, Issue 9, 2007, Pages 1077-1083

  Miwa, Hideto ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiepileptic drug; Parkinson's disease; Tremor; Zonisamide

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CALCIUM CHANNEL T TYPE; DOPAMINE; EXEGRAN; LEVODOPA; PLACEBO; UNCLASSIFIED DRUG; ZONISAMIDE;

ADD ON THERAPY; ANOREXIA; APATHY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSKINESIA; HALLUCINATION; HUMAN; MENTAL DISEASE; NONHUMAN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; WEIGHT REDUCTION;

ANTICONVULSANTS; ANTIPARKINSON AGENTS; BRAIN; CLINICAL TRIALS; HUMANS; ISOXAZOLES; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 34548826238     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.9.1077     Document Type: Review

References (43)

1. Leppik, Ilo E. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13(Suppl. 1), S5-S10 (2004).
2. Arzimanoglou A, Rahbani A. Zonisamide for the treatment of epilepsy. Expert Rev. Neurother. 6, 1283-1292 (2006).
3. Fukushima K, Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia 47, 1860-1864 (2006).
4. Ohtahara S. Zonisamide in the management of epilepsy - Japanese experience. Epilepsy Res. 68(Suppl. 2), S25-S33 (2006).
5. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin. Neuropharmacol. 27, 278-280 (2004).
6. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289, 1820-1825 (2003).
7. Wilson MS, Findling RL. Zonisamide for bipolar depression. Expert Opin. Pharmacother. 8, 111-113 (2007).
8. McElroy SL, Kotwal R, Guerdjikova AI. et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J. Clin. Psychiatry 67, 1897-1906 (2006).
9. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. 6(3), 225-234 (2005).
10. Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci. Res. 41, 397-399 (2001). • Open trials on new indication for zonisamide.
11. Murata M, Hasegawa K, Kanazawa I. The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68, 45-50 (2007). •• Important controlled trials of zonisamide.
12. Bonuccelli U, Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67(7 Suppl. 2), S30-S38 (2006).
13. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientificrationale and clinical implications. Lancet Neurol. 5, 677-687 (2006).
14. Stocchi F. Optimising levodopa therapy for the management of Parkinson's disease. J. Neurol. 252(Suppl. 4), IV43-IV48 (2005).
15. Uno H, Kurokawa M, Masuda Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2- benzisoxazole derivatives and their anticonvulsant activities. J. Med. Chem. 22, 180-183 (1979).
16. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 5, 115-119 (1996).
17. Okada M, Kaneko S, Hirano T et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 22, 193-205 (1995).
18. Okada M, Hirano T, Kawata Y et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 34, 187-197 (1999).
19. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3, 138-143 (1989).
20. Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H. Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med. J. Osaka Univ. 39, 13-17 (1990).
21. Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Mol. Brain Res. 116, 1-6 (2003).
22. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr. Pharm. Des. 10, 687-693 (2004).
23. Gluck MR, Santana LA, Granson H, Yahr MD. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J. Neural Transm. 111, 713-724 (2004).
24. Wichmann T, DeLong MR. Basal ganglia discharge abnormalities in Parkinson's disease. J. Neural Transm. 70, 21-25 (2006).
25. Wang L, Kitai ST, Xiang Z. Activitydependent bidirectional modification of inhibitory synaptic transmission in rat subthalamic neurons. J. Neurosci. 26, 7321-7327 (2006).
26. Wolfart J, Roeper J. Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons. J. Neurosci. 22, 3404-3413 (2002).
27. Gomez-Mancilla B, Latulippe JF, Boucher R, Bedard PJ. Effect of ethosuximide on rest tremor in the MPTP monkey model. Mov. Disord. 7, 137-141 (1992).
28. Pourcher E, Gomez-Mancilla B, Bedard PJ. Ethosuximide and tremor in Parkinson's disease: a pilot study. Mov. Disord. 7, 132-136 (1992).
29. Minato H, Kikuta C, Fujitani B, Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 38, 975-980 (1997).
30. Owen AJ, Ijaz S, Miyashita H, Wishart T, Howlett W, Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res. 770, 115-122 (1997).
31. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 30, 153-158 (1998).
32. Noda Y, Mori A, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res. Commun. Mol. Pathol. Pharmacol. 105, 23-33 (1999).
33. Komatsu M, Hiramatsu M, Willmore LJ. Zonisamide reduces the increase in 8-hydroxy-2′-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia 41, 1091-1094 (2000).
34. Nakasa H, Nakamura H, Ono S et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol. 54, 177-83 (1998).
35. Ohmori S, Nakasa H, Asanome K et al. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim. Biophys. Acta 1380, 297-304 (1998).
36. Stiff DD, Robicheau JT, Zemaitis MA. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica 22, 1-11 (1992).
37. Murata M, Hasegawa K, Kanazawa I. Randomized, double-blind study of zonisamide with placebo in advanced Parkinson's disease. Move. Disord. 19(Suppl. 9), S198 (2004).
38. Nakanishi, I, Kohmoto J, Miwa H, Kondo T. Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No To Shinkei 55, 685-689 (2003) (In Japanese).
39. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat. Disord. 11, 101-103 (2005).
40. Ondo WG, Khan F. Zonisamide for essential tremor. Move. Disord. 21(Suppl. 15), S705 (2006).
41. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Move. Disord. 22, 279-282 (2007).
42. Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats. Parkinsonism Relat. Disord. (2007) (In Press).
43. Ondo WG. Essential tremor: treatment options. Curr. Treat. Options Neurol. 8, 256-267 (2006).